Activity:

Adrenomedullin (1-50), rat is a 50 amino acid peptide, which induces a selective arterial vasodilation via activation of CGRP1 receptor. IC50 & Target: CGRP1 receptor^[1] In Vitro: Adrenomedullin (1-50), rat is a 50 amino acid peptide, which induces a selective arterial vasodilation via activation of CGRP1 receptor^[1]. In Vivo: Adrenomedullin (1-50), rat causes a dose-dependent and endothelium-independent vasodilation on the arterial mesenteric vasculature, and this effect is inhibited by CGRP1 receptor antagonist. Adrenomedullin (1-50), rat activates CGRP1 receptor in the double-perfused mesenteric bed of the rat^[1]. Adrenomedullin (1-50) ameliorates pulmonary vascular structural remodeling of hypoxic rats with incresed plasma NO and H(2)S concentrations. Adrenomedullin (1-50) also regulates the development of hypoxic pulmonary hypertension and hypoxic pulmonary vascular structural remodeling, through promoting NO and H(2)S production in hypoxic rats^[2].

Protocol:

Animal Administration: Adrenomedullin (1-50), rat is formulated in PBS^[1].^[1]Rats^[1]
Male albino Wistar rats (250-350 g) are used in the assay. Following an equilibration period of 45 min, the vasoactive effect of Adrenomedullin (1-50), rat, rADM (11-50), acetylcholine (ACh), and bradykinin (BK) is evaluated. The perfusion pressure on both sides of the mesenteric circulation is increased by infusing either a sympathomimetic, methoxamine (100 μM), on the arterial side or a thromboxomimetic, U46619 (0.5 μM), on the venous side. When a plateau is reached, the agents (Adrenomedullin (1-50), rat, etc.) are administered by bolus injections (1 to 45 μL). Vasodilator responses are expressed as percent reduction of induced tone on both sides of the mesenteric vasculature. In some experiments, the effects of the CGRP1 receptor antagonist hCGRP_8-37 and of the nitric oxide synthase inhibitor L-NAME are evaluated. They are infused 15 and 30 min, respectively, before the administration of the agonists^[1].

References:

• SDS